E
Cocrystal Pharma, Inc. COCP
$1.31 $0.000.00% NASDAQ
Recommendation
Prev Close
$1.31
Volume
1,728
Avg Vol (90D)
37,540
Market Cap
$13.33M
Dividend & Yield
--
52-Week Range
$1.12 - $3.26
P/E (TTM)
--
EPS (TTM)
-$1.72
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference
4/16/2025 - GuruFocus
Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference
4/16/2025 - Globe Newswire
Cocrystal Pharma Approves 2025 Equity Incentive Plan
4/8/2025 - TipRanks Financial Blog
Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral ...
3/31/2025 - GuruFocus
Cocrystal Pharma reports FY24 EPS ($1.72), consensus ($1.93)
3/31/2025 - The Fly
Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
3/31/2025 - Globe Newswire
Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual ...
3/6/2025 - GuruFocus
Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025
3/6/2025 - Globe Newswire
Cocrystal Pharma And 2 Other Promising US Penny Stocks To Watch
2/11/2025 - Simply Wall St
Cocrystal Pharma's Promising Drug Developments Garner Buy Rating from Analyst
1/22/2025 - TipRanks Financial Blog
Cocrystal Pharma reports Phase 1 safety, tolerability results of CDI-988
1/8/2025 - The Fly
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for ...
1/8/2025 - GuruFocus
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections
1/8/2025 - Globe Newswire
Cocrystal Pharma (NASDAQ: COCP) Extends Enrollment in Phase 2a Influenza StudyCocrystal Pharma, Inc., a clinical-stage biotechnology company, has announced plans to extend enrollment in the Phase 2a human challenge study for its oral influenza PB2 in
1/1/2025 - Ticker Report
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide
12/31/2024 - Benzinga
Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement
12/31/2024 - GuruFocus
Cocrystal Pharma Extends Enrollment for Influenza Study
12/31/2024 - TipRanks Financial Blog
Cocrystal Pharma to extend Phase 2a Influenza challenge study
12/31/2024 - The Fly
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
12/31/2024 - GuruFocus
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
12/31/2024 - Globe Newswire
Short Interest in Cocrystal Pharma, Inc. (NASDAQ:COCP) Grows By 150.0%
12/27/2024 - Ticker Report
How The Parts Add Up: DFSU Targets and#36;43
12/26/2024 - ETF Channel
Cocrystal Pharma reports Q3 EPS (49c), consensus (57c)
11/13/2024 - The Fly
Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
11/13/2024 - Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$17.75M
EBIT (TTM)
-$17.88M
Net Income (TTM)
-$17.50M
Balance Sheet
Total Assets (Q)
$13.46M
Total Debt (Q)
$1.81M
Total Liabilities (Q)
$3.93M
Book Value Per Share (Q)
$0.936
Cash Flow
Cash from Operations (TTM)
-$16.49M
Cash from Investing (TTM)
-$8.00K
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
-$16.49M
Filings
Filing Date
Monday, March 31, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
1.27
7-Day Total Return
10.08%
30-Day Total Return
-22.99%
60-Day Total Return
-37.14%
90-Day Total Return
-31.05%
Year to Date Total Return
-43.53%
1-Year Total Return
-12.37%
2-Year Total Return
-49.15%
3-Year Total Return
-79.40%
5-Year Total Return
-87.54%
52-week Low
Apr 09, 2025 - $1.12
52-week High
Dec 30, 2024 - $3.26
Valuation
Market Cap
$13.33M - Nano Cap
Enterprise Value
$5.27M
Price/Sales (TTM)
--
Price/Book (Q)
1.40
Dividends and Shares
Shares Outstanding
10.17M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.cocrystalpharma.com
Phone Number
877 262 7123
Address
19805 North Creek Parkway
Bothell, WA 98011
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based... more
NASDAQ 04/17/2025 11:08AM Eastern Quotes delayed